Ernst & Young LLP (EY US) announced that Marcus Gerhardt, co-founder and CEO, and Florian Solzbacher, co-founder and President, of Blackrock Neurotech were named Entrepreneur Of The Year^® 2023 Mountain West Award finalists. Now in its 37th year, Entrepreneur Of The Year is one of the preeminent competitive business awards for transformative entrepreneurs and leaders of high-growth companies who are building a more equitable, sustainable and prosperous world for all.

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced it has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica and Valence.

The times are changing in biopharma. With the top drugmakers no longer committing most of their resources to the pandemic, biopharma is returning to its roots. But it’s clear the world is quickly changing, and so too are the companies that make up our industry.

At the University of Utah, Chris Gibson was studying to become a physician-scientist and considering a career in R&D where he would search for medicines to cure serious diseases. He is now CEO of one of the industry’s most promising biotechs.

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces that the U.S. Food and Drug Administration (FDA) has removed its partial clinical hold on Salarius’ Phase 1/2 Ewing sarcoma clinical trial evaluating seclidemstat, Salarius’ novel oral, reversible, targeted LSD1 inhibitor.